CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days)
intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as
compared to sham in subjects with geographic atrophy.